avutometinib
avutometinib: sourced relationships with 1 company · 14 clinical trials tracked.
avutometinib evidence translation
What we can confirm
14 tracked trials
What it means
What to watch
Prepared research question
How could avutometinib → VSTM affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Verastem, Inc. (VSTM) Non Small Cell Lung Cancer; Low Grade Serous Ovarian Cancer;… | Phase 3 |
Clinical Trial Registry Records (14)showing 10 most recent
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
Primary endpoint: Safety and adverse events (AEs).
Phase II Study of Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Primary endpoint: Progression-free survival (PFS) - Experimental Arm Only
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
Primary endpoint: Safety and adverse events (AEs)
A Phase 1/2 Trial of the Doublet Combination of Avutometinib and Defactinib and as a Triplet in Combination With Temozolomide in Patients With High Grade Malignant Brain Tumours Within the 5G Platform
Primary endpoint: Phase 1b - To evaluate the safety and tolerability of investigational agent in patients with malignant brain tumours
A Phase II Trial of Avutometinib in Combination With Defactinib in Metastatic Diffuse Gastric Cancer
Primary endpoint: Progression-free survival (PFS) Rate
Combination Targeted and Hormonal treAtMEnt of Low-gradE Serous Ovarian Cancer in the upfroNt Setting
Primary endpoint: objective response rate
Phase 1b/2 Trial of Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
Primary endpoint: Response rate defined as Partial Response (PR) + Complete Response (CR) using Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria of all measurable target lesions present at the time of enrollment on trial.
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)
Primary endpoint: Progression Free Survival (PFS) per blinded independent central review (BICR)
Phase II of Avutometinib (VS-6766) and Defactinib In RAF Dimer-Driven RAI-Refractory Differentiated and Anaplastic Thyroid Cancer Patients
Primary endpoint: overall response rate (ORR) cohort A
A Single-Dose Study of Orally Administrated Defactinib or VS-6766 in Patients With Glioblastoma
Primary endpoint: Concentration of defactinib that accumulates in the glioblastoma (GBM) and brain around tumor
Frequently asked questions
Which companies have sourced relationships with avutometinib?
avutometinib has dated SEC/FDA relationship records for Verastem, Inc..
How many clinical trials involve avutometinib?
BioSniper tracks 14 clinical trials involving avutometinib.